Taysha Gene Therapies downgraded to neutral at Goldman Sachs on measured outlook

Nov. 09, 2022 11:55 AM ETTaysha Gene Therapies, Inc. (TSHA)ALPMF, ALPMYBy: Jonathan Block, SA News Editor4 Comments

Flag and Wall street sign

Fabrice Cabaud

  • Goldman Sachs has downgraded Taysha Gene Therapies (NASDAQ:TSHA) to neutral from buy saying it has a more measured outlook on its portfolio.
  • The firm also cut its price target to $3 from $16 (~36% upside based on Tuesday's close).
  • Analyst Salveen Richter said that while she is encouraged by the recent strategic investment by Astellas Pharma (OTCPK:ALPMF)(OTCPK:ALPMY), she is hesitant on the stock due to the company's reprioritization of assets.
  • She is removing gene therapy programs for SLC6A1, SURF1, CLN1 from her model.
  • Seeking Alpha's Quant Rating views Taysha (TSHA) as a strong sell.

Recommended For You

Comments (4)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.